Search Press releases Keywords From To 21 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Read More 19 Jan 2022 UCB to acquire Zogenix Read More 18 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study Read More 8 Jan 2022 Disposals of own shares Read More 3 Jan 2022 Disposals of own shares Read More 21 Dec 2021 Disposals of own shares Read More Pagination First page Previous page Previous … Page 43 Page 44 Page 45 Page 46 Current page 47 Page 48 Page 49 Page 50 Page 51 … Page 47 of 60 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
